European Pharma Stocks Benefiting from U.S. Drug Pricing Deal

25 days ago

Chloe Malay

"AstraZeneca, but also Novartis, Rush, Novonordis, all of them were up this morning across that pharma sector on the back of Pfizer's deal with Trump on drug pricing. ... what JP Morgan analysts have said is that this could kind of act as a bellwether for that pharmaceutical sector and that European pharma companies could potentially strike similar deals with the US administration."

The discussion highlights that European pharmaceutical stocks, including AstraZeneca and Novartis, are rallying following a major pricing deal by Pfizer with the U.S. administration. Analysts suggest that similar deals might be negotiated by other European pharma companies to mitigate the impact of high tariffs on branded drugs, which could serve as a positive catalyst for the sector.

Related Stocks